Home Overview Press Room Blog Publications For Students about us
Search

About the States' Policies & Human Biotechnology


Individual states are filling the regulatory void created by the federal government’s failure to provide comprehensive legislation governing human biotechnologies. This is creating an often inconsistent policy patchwork.

California

State action is evident in a number of areas, including embryonic stem cell, cloning, egg retrieval, and assisted reproduction. More than a dozen states have laws banning reproductive cloning, about half of which also prohibit cloning for stem cell research. Dozens of similar bills are introduced in other states each year.

In response to President Bush’s restrictions on the federal funding of human embryonic stem cell research, several states initiated their own funded research programs. California led the way in 2004 with Proposition 71, which set aside $3 billion of public funds for stem cell research over ten years.



‘Moonshot’ Medicine Will Let Us Downby Michael J. JoynerThe New York TimesJanuary 29th, 2015President Obama's new budget is expected to include hundreds of millions of dollars for so-called precision medicine but this is unlikely to make most of us healthier.
Stem Cell Clinics, FDA, and Giant, Unapproved For-Profit Human Experimentsby Paul KnoepflerKnoepfler Lab Stem Cell BlogJanuary 27th, 2015The for-profit clinic argument for stem cell deregulation and weakening of the FDA’s role in regulating stem cell products is a direct challenge to our system of science-based medicine.
Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testingby Andrew PollackThe New York TimesJanuary 27th, 2015The company has settled or is in the process of settling patent-infringement lawsuits it filed against other companies that now offer such testing.
Obama to Request Research Funding for Treatments Tailored to Patients’ DNAby Robert PearThe New York TimesJanuary 24th, 2015President Obama will seek hundreds of millions of dollars for a new initiative to develop medical treatments tailored to genetic and other characteristics of individual patients.
Riding High, Biotech Firms Remain Waryby Andrew PollackThe New York TimesJanuary 18th, 2015The biotech business is experiencing an almost unprecedented boom. Money is flowing into the industry as never before. Stock prices are high, and drug approvals are up. Some say it's a bubble that will burst.
State Courts Strike Blows to Criminal DNA Collection Laws in 2014—What to Look for in 2015by Jennifer LynchElectronic Frontier FoundationJanuary 5th, 2015The "slippery slope toward ever-expanding warrantless DNA testing" is already upon us. But recent state cases provide reason for hope.
How the Rise of Commercial Surrogacy is Turning Babies into Commoditiesby Clair AchmadThe ConversationDecember 25th, 2014This year the international spotlight turned with full force on cross-border commercial surrogacy.
White? Black? A Murky Distinction Grows Still Murkierby Carl ZimmerThe New York TimesDecember 24th, 2014There is a long tradition of trying to draw sharp lines between ethnic groups, but our ancestry is a fluid and complex matter, geneticists say.
Commercialized Conception Casualties: "Brave" Baby Making?by Mirah RibenHuffington PostDecember 22nd, 2014Hiring surrogates and purchasing sperm, eggs, or others' leftover frozen embryos have become accepted as choices on a menu of options.
The ‘Science’ of Eugenics: America’s Moral Detourby Marilyn M. SingletonJournal of American Physicians and SurgeonsDecember 15th, 2014Within 100 years, our deep thinkers went from declaring that in our new country “all men are created equal” to espousing the idea that “some men are more equal than others.”
Displaying 1-10 of 355  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760